T
TRAVERE THERAPEUTICS INC
NASDAQ: TVTX (Travere Therapeutics, Inc.)
最近更新时间: 4小时之前58.85
-0.18 (-0.30%)
| 前收盘价格 | 59.03 |
| 收盘价格 | 59.34 |
| 成交量 | 4,126,165 |
| 平均成交量 (3个月) | 2,543,666 |
| 市值 | 5,472,632,320 |
| 预期市盈率 (P/E Forward) | 80.65 |
| 价格/销量 (P/S) | 9.89 |
| 股市价格/股市净资产 (P/B) | 55.43 |
| 52周波幅 |
| 营业毛利率 | -82.88% |
| 营业利益率 (TTM) | -52.21% |
| 稀释每股收益 (EPS TTM) | -2.78 |
| 季度收入增长率 (YOY) | 97.50% |
| 总债务/股东权益 (D/E MRQ) | 1,220.07% |
| 流动比率 (MRQ) | 2.05 |
| 营业现金流 (OCF TTM) | -160.66 M |
| 杠杆自由现金流 (LFCF TTM) | -239.23 M |
| 资产报酬率 (ROA TTM) | -23.21% |
| 股东权益报酬率 (ROE TTM) | -422.66% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Travere Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.4
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.38 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.75% |
| 机构持股比例 | 113.30% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Janus Henderson Group Plc | 31 Mar 2026 | 11,419,586 |
| Armistice Capital, Llc | 31 Mar 2026 | 4,897,417 |
| Perceptive Advisors Llc | 31 Mar 2026 | 4,142,551 |
| Nomura Investment Management Business Trust | 31 Mar 2026 | 3,270,513 |
| Stephens Investment Management Group Llc | 31 Mar 2026 | 1,798,466 |
| Kynam Capital Management, Lp | 31 Mar 2026 | 1,569,018 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合